Medicament for preventing or treating papilloma virus-specific tumor

Abstract

The present invention relates to a pharmaceutical composition for the avoidance or treatment of human papillomavirus (HPV)-specific tumour comprising at least one fusion protein from at least one L1 protein of one or more papillomaviruses and at least one E protein of one or more papillomaviruses, the fusion protein containing no papillomavirus-unspecific epitopes. In some embodiments, the pharmaceutical composition further comprises suitable additives and/or excipients.

1 . Medicament for the avoidance or treatment of human papillomavirus (HPV)-specific tumour comprising at least one fusion protein from at least one L1 protein of one or more papillomaviruses and at least one E protein of one or more papillomaviruses and, if appropriate, suitable additives and/or excipients, wherein the fusion protein contains no papillomavirus-unspecific epitopes.  
     
     
         2 . Medicament according to  claim 1 , wherein the tumour is a carcinoma of the larynx, cervix, penis, vulva or anus.  
     
     
         3 . Medicament according to  claim 1 , wherein the medicament contains no adjuvant.  
     
     
         4 . Medicament according to  claim 1 , wherein the additive or excipient is about 0.3 to about 4 M of a salt having a pH of about 7.3 to about 7.45.  
     
     
         5 . Medicament according to  claim 4 , wherein the salt is an alkali metal or alkaline earth metal salt.  
     
     
         6 . Medicament according to  claim 4 , wherein the pH is adjusted using a buffer.  
     
     
         7 . Medicament according to claims  1 , wherein the L1 protein is a deleted L1 protein.  
     
     
         8 . Medicament according to  claim 7 , wherein the L1 protein is a C-terminally deleted L1 protein.  
     
     
         9 . Medicament according to  claim 7 , wherein up to about 35 amino acids are deleted from the L protein.  
     
     
         10 . Medicament according to  claim 1 , wherein the E protein is a deleted E protein.  
     
     
         11 . Medicament according to  claim 10 , wherein the deleted E protein is a C-terminally deleted E protein.  
     
     
         12 . Medicament according to  claim 10 , wherein up to about 55 amino acids are deleted.  
     
     
         13 . Medicament according to  claim 1 , wherein the fusion protein is present in the form of a capsid and/or capsomer.  
     
     
         14 . Medicament according to  claim 1 , wherein the HPV is selected from the group consisting of HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-42, HPV-45, HPV-52 and/or HPV-58.  
     
     
         15 . Medicament according to  claim 14  in the form of a combination vaccine, wherein the papillomaviruses are selected from the group consisting of HPV-16 and HPV-18 or HPV-18, HPV-31, HPV-45 and HPV-58 or HPV-6 and HPV-11.